Biofrontera INC S-1 registration statements

Biofrontera Inc. files an S-1 registration statement for the resale of 4,000,640 common shares by selling stockholders, with no proceeds going to the company.

Biofrontera Inc. announces the acquisition of full U.S. rights to its key product Ameluz and a significant common stock resale offering by selling stockholders, while facing ongoing financial challenges and potential dilution.

Biofrontera Inc. has filed an S-1 registration statement to allow selling stockholders to resell 13,602,176 shares of common stock issued from the conversion of Series C Convertible Preferred Stock, with the company not receiving any proceeds from these sales.

Biofrontera Inc. has filed a registration statement for the resale of up to 5.7 million shares of common stock by selling stockholders, primarily stemming from the conversion of senior secured convertible notes.

Biofrontera Inc. has filed a registration statement for the potential resale of up to 11,309,019 shares of common stock by selling stockholders, issuable upon conversion of Series B-3 Convertible Preferred Stock.

Biofrontera Inc. has filed an amendment to its registration statement for the resale of up to 9,310,678 shares of common stock by selling stockholders.

Biofrontera Inc. has filed a registration statement for the resale of up to 9,310,678 shares of common stock by selling stockholders after a recent private placement.

Biofrontera Inc. is offering up to 3,300,000 shares of common stock and warrants in a best efforts offering to raise capital for general corporate purposes.

Biofrontera Inc. announces a proposed public offering of common stock and warrants to fuel working capital and growth initiatives.